Compounded Eczema and Dermatitis Treatment

Compounded cream for eczema and dermatitis, prepared to prescription in Kuala Lumpur

Medically reviewed by: Vitthia Rama Murti, BPharm Hons (University of Cyberjaya), RPh 15632 — Chief of Staff & Compounding Pharmacist, Lynnity Compounding Pharmacy.
Last reviewed: 27 October 2026.

Eczema and dermatitis

Atopic dermatitis is itchy, relapsing skin inflammation that flares and settles. Topical corticosteroids are the usual prescribed treatment for a flare, and the practical questions for a prescriber are which strength, in which vehicle, for how long, and with which excipients left out.

Betamethasone valerate 0.1% is one of the corticosteroids that has been studied in atopic dermatitis. The trials below are the ones our prescriber’s guide examines.

Strengths and schedules in the cited trials

StudyStrength and vehicleSchedulePMID
Danby et al., 20140.1% betamethasone valerate creamTwice daily for 4 weeks24328907
Gether et al., 20250.1% betamethasone 17-valerate ointment, whole-bodyOnce daily for 2 weeks, then twice weekly for 4 weeks39078120
Gether et al., 20230.1% betamethasone 17-valerate, whole-bodyOnce daily for 2 weeks, then twice weekly for 4 weeks36824052

What these trials reported

  • Skin barrier. The 2014 trial reported that betamethasone valerate cream "significantly reduced skin barrier function, integrity and cohesion", while tacrolimus 0.1% "preserved skin barrier function, integrity, cohesion", and that 4 weeks of treatment "adversely affected the biophysical properties of the skin" (PMID 24328907).
  • Bone formation. In the 2023 adult trial, the bone formation marker P1NP decreased after betamethasone 17-valerate 0.1% at 2 and 6 weeks, while the bone resorption marker CTX was unchanged. The authors wrote that the negative impact on bone formation "could be regarded an adverse effect of TCS" (PMID 36824052).
  • What the designs cannot show. The 2014 trial was conducted in volunteers without active disease. The 2025 and 2023 trials used whole-body treatment in adults with active atopic dermatitis, which is the setting in which systemic effects were measured. None of the three compares betamethasone with a corticosteroid other than itself.

Where compounding fits

Compounding is useful here for three reasons: the prescriber can set the strength and the vehicle rather than accept a commercial pairing, an excipient a patient reacts to can be left out, and a second active can be included where the prescriber has specified one for that patient.

Lynnity prepares non-sterile preparations only: capsules, oral liquids and suspensions, creams, gels, sprays, powders, tonics and serums, each available in a liposomal or an ordinary form. Every preparation is made for one named patient on a registered doctor’s prescription, under Good Compounding Practice.

Points for the prescriber

  • Each cited trial is a short course. The length of treatment, and the review points, are the prescriber’s to set and record.
  • Whole-body application is the setting in which the systemic signal above was measured, so the area of application belongs in the directions.
  • Where a patient reacts to a preservative or another excipient, state the exclusion on the prescription and we will select an alternative vehicle.

How to start

Speak to your doctor. If a compounded preparation is appropriate, the prescription is sent to us naming the patient, the active, the strength, the form, the quantity and the directions for use. We review it for compatibility and stability before preparing, and contact the clinic if anything needs clarifying. Our details are on the contact page.

Read the evidence in full

Betamethasone for Eczema and Dermatitis: What the 2026 Evidence Shows for Malaysian Prescribers sets out each trial, what it measured and what it cannot support.

See also: choosing a compounded cream for eczema and dermatology compounding.

FAQ

Can a compounded preparation for eczema be supplied without a prescription?

No. Each preparation is made for one named patient on a registered doctor’s prescription.

What strength did the eczema trials use?

0.1% betamethasone throughout, as valerate in the 2014 cream and as 17-valerate in the 2025 and 2023 whole-body trials.

Does betamethasone affect bone formation?

In the 2023 whole-body trial the bone formation marker P1NP decreased at 2 and 6 weeks while the resorption marker CTX was unchanged, and the authors suggested this could be regarded as an adverse effect of topical corticosteroids (PMID 36824052). That trial used intensive whole-body treatment, not a small area.

Is the evidence for betamethasone in eczema strong?

It is limited. Three short-course trials, one of them in volunteers without active disease, and no comparison against a different corticosteroid.

WhatsApp us